BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Core Insights - BioMarin Pharmaceutical reported revenue of $825.41 million for the quarter ended June 2025, reflecting a year-over-year increase of 15.9% [1] - The company's EPS was $1.44, up from $0.96 in the same quarter last year, indicating a significant improvement in profitability [1] - The reported revenue exceeded the Zacks Consensus Estimate of $766.23 million by 7.72%, and the EPS surpassed the consensus estimate of $1.03 by 39.81% [1] Revenue Breakdown - Net product revenues totaled $812.98 million, exceeding the average estimate of $755.45 million by analysts, marking a 15.8% increase year-over-year [4] - Royalty and other revenues reached $12.43 million, surpassing the estimated $10.77 million, representing a 25.5% increase compared to the previous year [4] - Specific product revenue highlights include: - NAGLAZYME: $129 million, slightly below the estimate of $120.87 million, a decrease of 2.3% year-over-year [4] - VIMIZIM: $215 million, exceeding the estimate of $186.74 million, a 20.8% increase [4] - PALYNZIQ: $106 million, above the estimate of $100.63 million, a 20.1% increase [4] - VOXZOGO: $221 million, slightly above the estimate of $219.28 million, a 20.2% increase [4] - ROCTAVIAN: $9 million, below the estimate of $12.52 million, a 21.6% increase [4] - KUVAN: $27 million, exceeding the estimate of $21.49 million, a decrease of 5.6% [4] - ALDURAZYME: $56 million, surpassing the estimate of $43.18 million, a significant increase of 45.1% [4] - BRINEURA: $49 million, above the estimate of $45.89 million, an 8.2% increase [4] Stock Performance - BioMarin's shares have returned +1.1% over the past month, outperforming the Zacks S&P 500 composite's +0.6% change [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]